uniQure N.V. (QURE) Jumps: Stock Adds 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:51AM CST
uniQure N.V. (QURE) was a big mover last session, as its shares rose over 6% on the day.
QURE: 14.75 (+0.22), ANIP: 55.24 (+1.79), ILMN: 186.22 (+2.72), AFFX: 9.80 (+0.05)
uniQure to Present at the Oppenheimer 25th Healthcare Conference - NYC
GlobeNewswire - Fri Dec 05, 4:09AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th Healthcare Conference - NYC, to be held December 10-11, 2014, at The Crowne Plaza Hotel in New York City, NY, USA.
QURE: 14.75 (+0.22)
uniQure reports Q3 results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:37AM CST
QURE: 14.75 (+0.22)
uniQure EPS of -€0.51
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 6:52AM CST
QURE: 14.75 (+0.22)
uniQure Announces Results for the Third Quarter of 2014
GlobeNewswire - Mon Dec 01, 6:33AM CST
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the third quarter of 2014.
QURE: 14.75 (+0.22)
uniQure N.V. (QURE) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:21AM CST
uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise by nearly 19% on the day.
QURE: 14.75 (+0.22), ANIP: 55.24 (+1.79), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05)
UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST
BIS: 47.26 (-1.74), QURE: 14.75 (+0.22), BIB: 122.51 (+3.83), ALXN: 181.96 (+3.09), IBB: 299.80 (+5.12)
Uniqure (QURE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:32AM CST
Uniqure (QURE) Shares March Higher, Can It Continue?
QURE: 14.75 (+0.22)
uniQure to Host Investor Day in New York City
GlobeNewswire - Fri Nov 21, 8:34AM CST
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on December 1, 2014, starting at 8:30 a.m. uniQure management will be joined by distinguished guests to discuss the Company's strategy, clinical programs and uniQure's vision of how gene therapy will change the future of medicine.
QURE: 14.75 (+0.22)
uniQure to Present at Jefferies Global Healthcare Conference - London
GlobeNewswire - Mon Nov 10, 4:03AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Jorn Aldag, CEO, will present a corporate overview at Jefferies Global Healthcare Conference - London, to be held November 19-20, 2014.
QURE: 14.75 (+0.22)
AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data from Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate
GlobeNewswire - Mon Oct 27, 5:45AM CDT
--Top-line Results Confirming Safety, Liver Transfection Presented at ESGCT Conference--
QURE: 14.75 (+0.22)
uniQure to Present at the Leerink Partners Rare Disease Roundtable Conference
GlobeNewswire - Thu Sep 25, 8:08AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present at the Leerink Partners Rare Disease Roundtable Conference, October 1st, 2014, to be held at the Le Parker Meridien Hotel, New York City, NY, USA.
QURE: 14.75 (+0.22)
uniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs
GlobeNewswire - Tue Sep 02, 5:15AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the second quarter of 2014 and an update on multiple gene therapy programs.
QURE: 14.75 (+0.22)
Can the Rally in Uniqure (QURE) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 8:29AM CDT
Can the Rally in Uniqure (QURE) Shares Continue?
QURE: 14.75 (+0.22)
uniQure Acquires Cardiology Gene Therapy Company InoCard
GlobeNewswire - Mon Aug 11, 3:35PM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease affecting 26 million people worldwide. InoCard founders Prof. Patrick Most and Prof. Hugo Katus will join uniQure as Managing Director of uniQure in Germany and Chairman of the Scientific Advisory Board, for Cardiovascular Diseases, respectively.
QURE: 14.75 (+0.22)
Chiesi and uniQure Provide Update on Glybera(r) Launch
GlobeNewswire - Mon Aug 04, 6:11AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"
QURE: 14.75 (+0.22)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
NVEE: 12.78 (-0.19), PBHC: 9.81 (+0.01), BB.TO: 12.41 (-0.17), IRMD: 12.64 (+0.14), QURE: 14.75 (+0.22), BBRY: 10.67 (-0.13), SAL: 26.77 (+0.27), BRID: 7.01 (-0.45), POZN: 7.86 (+0.07), SNDK: 100.65 (+0.27)
uniQure Secures Additional $10M Venture Loan from Hercules Capital
GlobeNewswire - Tue Jul 01, 4:16AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of an additional $10 million venture debt loan with Hercules Technology Growth Capital, Inc. (HTGC), increasing the total loan amount to $20 million including the initial $10 million that uniQure announced in July 2013.
HTGC: 15.13 (+0.39), QURE: 14.75 (+0.22)
uniQure and Medison Sign Glybera Distribution Agreement for Israel
PR Newswire Europe - Wed Jun 18, 8:27AM CDT
AMSTERDAM and PETACH TIKVA, Israel, June 18, 2014 /PRNewswire/ --
QURE: 14.75 (+0.22)